1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2527)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5914)
  2. GSK Faculty (5697)
  3. Department of Medicine (4259)
  4. Department of Pathology and Laboratory Medicine (3037)
  5. Tow Center for Developmental Oncology (TCDO) (2613)
  6. Solid Tumor Oncology Division (2600)

More Groups

People
  1. Marc Ladanyi (1327)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (120)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (263)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (758)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5914)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dual genetic targeting of ERK1 and ERK2 abrogates the competitive potential of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J.; Tsakiris, D.; Neel, B.; Levine, R.; Meyer, S.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • AKT mutant allele-specific activation dictates pharmacologic sensitivities
    Meeting Abstract

    Shrestha Bhattarai, T.; Shamu, T.; Patel, S.; Gorelick, A.; Chang, M. T.; Gavrila, E. I.; Gao, J. J.; Donoghue, M. T. A.; Gao, P. S.; Soumerai, T.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Delta-like ligand 3 (DLL3) is a novel target for molecular imaging of neuroendocrine prostate cancer
    Meeting Abstract

    Korsen, J.; Kalidindi, T.; Khitrov, S.; Khuram, H.; Piorier, J.; Rudin, C.; Chen, Y.; Pillarsetty, N. V. K.; Lewis, J.
    Journal of Nuclear Medicine (2020)

    Fulltext@MSK | Save
  • Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of immune-related adverse events (irAEs) with improved clinical outcome in sarcoma patients treated with immune checkpoint blockade (ICB)
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Kelly, C. M.; Kiesler, H.; Martindale, M.; Nicholls, C.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers
    Meeting Abstract

    Park, W.; Sokol, E.; Chen, J.; Yu, K. H.; Khalil, D.; Harding, J. J.; El Dika, I. H.; Riaz, N.; Abou-Alfa, G. K.; Kelsen, D. P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Peritoneal mesotheliomas characterized by less cell-cycle alterations and more TRAF7 alterations than malignant pleural mesotheliomas
    Meeting Abstract

    Offin, M.; Egger, J. V.; Cercek, A.; Nash, G. M.; Ladanyi, M.; Zauderer, M. G.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effects of radiation therapy on clonal hematopoiesis
    Meeting Abstract

    Modlin, L. A.; Wijetunga, N. A.; Patel, M.; Gao, T.; Ptashkin, R.; Sullivan, M. R.; Kelly, D. W.; Caltabellotta, N.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population
    Meeting Abstract

    Mellinghoff, I. K.; Peters, K. B.; Cloughesy, T. F.; Burris, H. A. 3rd; Maher, E. A.; Janku, F.; Cote, G. M.; De La Fuente, M. I.; Clarke, J. L.; Kha, L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save